ANY ONE of the following in 100-120 . (5
(A) The info graphic given below shows the risk of COVID-19 fatalities in different age brackets and
sender
Write a paragraph analyzing the given data.
8.9
MORTALITY RISK RISES WITH AGE
Cases Deaths
Fatality rate
Below 40 1.911
40 to 50 1,383 33
Above 60 773 69
Male 3,091 80
Feinale 976 29
Total 4067 109
Source: Calculated from health ministry data released on Apr 6
TOT FOR MORE INDONASINS DOWNLOAD
2.5
3.0
Image credit: Times of India
Answers
Kim G-U, Kim M-J, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26: 948.e1–948.e3.
Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-M, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94: 154–155.
Lau H, Khosrawipour T, Kocbach P, Ichii H, Bania J, Khosrawipour V. Evaluating the massive underreporting and undertesting of COVID-19 cases in multiple global epicenters. Pulmonology. 2020. doi:10.1016/j.pulmoe.2020.05.015
Niehus R, De Salazar PM, Taylor AR, Lipsitch M. Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China. Lancet Infect Dis. 2020;20: 803–808.
World Health Organization. Global surveillance for COVID-19 caused by human infection with COVID-19 virus. Available from: https://www.who.int/publications/i/item/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance
World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as a cause of death. Available from: https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19.pdf?ua=1
Metcalf CJE, Farrar J, Cutts FT, Basta NE, Graham AL, Lessler J, et al. Use of serological surveys to generate key insights into the changing global landscape of infectious disease. Lancet. 2016;388: 728–730.
Kritsotakis E. On the Importance of Population-Based Serological Surveys of SARS-CoV-2 Without Overlooking Their Inherent Uncertainties. doi:10.20944/preprints202005.0194.v1.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/serology-in-the-context-of-covid-19
Perez-Saez FJ, Lauer SA, Kaiser L, Regard S, Delaporte E, Guessous I, et al. Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland. Lancet Infect Dis doi:10.1016/S1473-3099(20)30584-3
Stringhini S, Wisniak A, Piumatti G, Azman AS, Lauer SA, Baysson H, et al. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study. Lancet. 2020. doi:10.1016/S0140-6736(20)31304-0.
The infection fatality rate of COVID-19 in Stockholm – Technical report. Available: https://www.folkhalsomyndigheten.se/contentassets/53c0dc391be54f5d959ead9131edb771/infection-fatality-rate-covid-19-stockholm-technical-report.pdf
Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JA. Early epidemiological assessment of the virulence of emerging infectious diseases: a case study of an influenza pandemic. PLoS One. 2009;4(8):e6852. Published 2009 Aug 31. doi:10.1371/journal.pone.0006852.
Ghani AC, Donnelly CA, Cox DR, Griffin JT, Fraser C, Lam TH, et al. Methods for estimating the case fatality ratio for a novel, emerging infectious disease. Am J Epidemiol. 2005;162: 479–486.
Lipsitch M, Donnelly CA, Fraser C, Blake IM, Cori A, Dorigatti I, et al. Potential Biases in Estimating Absolute and Relative Case-Fatality Risks during Outbreaks. PLOS Neglected Tropical Diseases. 2015. p. e0003846. doi:10.1371/journal.pntd.0003846.
Gold MS, Sehayek D, Gabrielli S, Zhang X, McCusker C, Ben-Shoshan M. COVID-19 and comorbidities: a systematic review and meta-analysis. Postgrad Med. 2020; 1–7.
Jain V, Yuan J-M. Predictive symptoms and comorbidities for severe COVID-19 and intensive care unit admission: a systematic review and meta-analysis. Int J Public Health. 2020;65: 533–546.
Pan D, Sze S, Minhas JS, Bangash MN, Pareek N, Divall P, et al. The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. EClinicalMedicine. 2020;23: 100404.
Angelopoulos A, Pathak R, Varma R, Jordan MI. Identifying and Correcting Bias from Time- and Severity- Dependent Reporting Rates in the Estimation of the COVID-19 Case Fatality Rate. SSRN Electronic Journal. doi:10.2139/ssrn.3556644.
WHO continues to monitor the situation closely for any changes that may affect this scientific brief. Should any factors change, WHO will issue a further update. Otherwise, this scientific brief document will expire 2 years after the date of publication.